Availability of interlrulkin 12 for gene therapy of hepatoma

Interlrulkin 12用于肝癌基因治疗的可用性

基本信息

  • 批准号:
    09044294
  • 负责人:
  • 金额:
    $ 3.14万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for international Scientific Research
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 无数据
  • 项目状态:
    已结题

项目摘要

We investigated the availability of ilterleulkin (IL) -12 for the gene therapy of hepatoma as a joint research with Dr,. Eda T. Bloom in FDA in the United State. We made a rat cirrhotic liver with use of thioacetamide as a in vivo model to evaluate the efficacy of IL-12 for the therapy of human hepatoma. We implanted AH66F cells, syngenic hepatoma cells, beneath the capsule of rat liver and performed the intra-peritoneal administration of IL-12. Tumor weight measured 7 weeks after administration was 0.7g, which was significantly lower than control (2.2g). On the contrary, IL-12 has an adverse effect to the liver when administrated in vivo. To reduce the dose of IL-12, we examine the synergistic effect of IL-12 and IL-18, which can induce IL-12 receptors on NK or T cells. IL-18 enhanced IL-12 mediated cytotoxic activity of separated human NK cells. We investigated the intracellular optimal microenvironment where NK cells can have high cytotoxic activity. The citotoxic activity of NK cel … More ls from cirrhotic rat liver or resected human liver bearing cirrhosis and hepatoma was significantly impaired, N-acetylcystein (NAC), the precursor of glutathione, resored their activity up to normal level in vitro. Further more, in vivo administration of both IL-12 and NAC suppressed the progression of tumors implanted in cirrhotic rat liver (0.3g). On the other hand, we planned to introduce IL-12 gene to liver cells. IL-12 gene (p40 and p35 were provided by Genetic Institute, USA. As preliminary assay, β-galactosidase gene with chicken β-actin promoter (LacZ) and FITC labeled oligodeoxynucleotide (FITC-ODN) were prepared. HVJ-liposome or HVJ-cationic liposome was prepared as follows ; dried lipids containing phosphatidylserine or DC cholesterol were mixed for liposome or cationic-liposome, respectively. These suspensions were incubated with DNA or FITC-ODN and inactivated HVJ. Hep3B and Huh7 (human hepatoma cell line) were transfected with these liposome complexes. These were directly injected into Wister rat liver in vivo. In order to detect the cellular uptake of FITC-ODN, transfected cells or livers were examined by fluorescent microscopy. X-gal staining was performed 72 hours after the injection of HVJ-liposome containing LacZ. After transfection of HVJ-liposome containing LacZ, only 2 or 3% of the Hep3B and Huh7 cells were positive in X-gal staining. However, fluorescence was detected in almost all cells even at 30 minutes after transfection of HVJ-cationic liposome containing EITC-ODN, especially 50-60% of nucleus of cells were accumulated. X\gal staining of rat liver transfected with HVJ-liposome containing LacZ revealed that 57% cells of hepatocytes were positive. In contrast, fluorescence was observed only in non-parenchymal cells in vivo after transfection of HVJ-cationic liposome containing FITC-ODN, probably due to interference by non-parenchymal cells. Although IL-12 expression was not detected by Western blotting nor ELLISA by now, the combination therapy of IL-12 by HVJ-liposome method with IL-18 or NAC may mediate the optimal cytotoxic activity of liver lymphocytes. Less
我们与Dr,共同研究了IL-12在肝癌基因治疗中的应用。埃达·T Bloom在美国的FDA。我们用硫代乙酰胺制作大鼠肝硬化模型,以评价IL-12对人肝癌的治疗效果。我们将AH 66 F细胞(同系肝癌细胞)植入大鼠肝被膜下,并进行IL-12腹腔内给药。给药后7周测量的肿瘤重量为0.7g,显著低于对照组(2.2g)。相反,IL-12在体内给药时对肝脏具有不利影响。为了减少IL-12的剂量,我们检查了IL-12和IL-18的协同作用,其可以诱导NK或T细胞上的IL-12受体。IL-18增强IL-12介导的分离的人NK细胞的细胞毒活性。我们研究了NK细胞可以具有高细胞毒活性的细胞内最佳微环境。NK细胞的细胞毒活性 ...更多信息 在离体条件下,谷胱甘肽前体N-乙酰半胱氨酸(NAC)的活性恢复到正常水平。此外,在体内施用IL-12和NAC两者抑制了移植在肝硬化大鼠肝脏(0.3g)中的肿瘤的进展。另一方面,我们计划将IL-12基因导入肝细胞。IL-12基因(p40和p35)由美国遗传研究所提供。作为初步试验,制备了带有鸡β-actin启动子的β-半乳糖苷酶基因(LacZ)和FITC标记的寡核苷酸(FITC-ODN)。如下制备HVJ-脂质体或HVJ-阳离子脂质体;将含有磷脂酰丝氨酸或DC胆固醇的干燥脂质分别混合用于脂质体或阳离子脂质体。将这些悬浮液与DNA或FITC-ODN和灭活的HVJ一起孵育。用这些脂质体复合物转染Hep 3B和Huh 7(人肝癌细胞系)。将这些直接注射到体内Wister大鼠肝脏中。为了检测细胞对FITC-ODN的摄取,通过荧光显微镜检查转染的细胞或肝脏。在注射含有LacZ的HVJ-脂质体后72小时进行X-gal染色。转染含LacZ的HVJ脂质体后,只有2%或3%的Hep 3B和Huh 7细胞在X-gal染色中呈阳性。而含EITC-ODN的HVJ-阳离子脂质体转染30 min后,几乎所有细胞都能检测到荧光,尤其是50-60%的细胞核聚集。用含LacZ的HVJ-脂质体转染大鼠肝细胞,经Xgal染色,阳性率为57%。与此相反,在体内转染HVJ-阳离子脂质体后,仅在非实质细胞中观察到荧光,可能是由于非实质细胞的干扰。虽然目前尚未用Western blotting和ELISA检测到IL-12的表达,但HVJ-脂质体法IL-12与IL-18或NAC的联合治疗可能介导肝淋巴细胞的最佳细胞毒活性。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tetsuro Hirose: "Oxygen dependency of epidermal grwoth factor receptor binding and DNA synthesis of rat hepatocytes" Journal of Hepatology. vol.27. 1081-1088 (1997)
Tetsuro Hirose:“表皮生长因子受体结合和大鼠肝细胞 DNA 合成的氧依赖性”肝脏病学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Akira Yamauchi: "Control of cell cycle Progression in Human NK cells through Redox Regulation of Expression and Phosphorylation of RB Protein"Blood. 89. 4092-4099 (1997)
Akira Yamauchi:“通过氧化还原调节 RB 蛋白的表达和磷酸化来控制人类 NK 细胞的细胞周期进展”血液。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Shigeru Tsuyuki, Akira Yamauchi, Hajime Nakamura, Yoshiaki Nakamura, Koichi Kinoshita, Takashi Gomi, Yasuhiro Kawai, Tetsuro Hirose, Keizo Furuke, Iwao Ikai, Katsuyuki Ohmari, Takashi Inamoto, and Yoshio Yamaoka: "N-acetykcysteine improves cytotoxic activ
Shigeru Tsuyuki、Akira Yamauchi、Hajime Nakamura、Yoshiaki Nakamura、Koichi Kinoshita、Takashi Gomi、Yasuhiro Kawai、Tetsuro Hirose、Keizo Furuke、Iwao Ikai、Katsuyuki Ohmari、Takashi Inamoto 和 Yoshio Yamaoka:“N-乙酰半胱氨酸改善细胞毒性活性
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Shigeru Tsuyuki, Takashi Inamoto, Yoshiaki Nakamura, Koichi Kinoshita, Takashi Gomi, Yoshiharu Shirakata, Toshiyuki Kitai, Akiyoshi Kanazawa, Akira Yamauchi, and Yoshio Yamaoka.: "Recombinant interleukin-2 therapy for angiosarcoma of the breast ; Efficacy
Shigeru Tsuyuki、Takashi Inamoto、Yoshiaki Nakamura、Koichi Kinoshita、Takashi Gomi、Yoshiharu Shirakata、Toshiyuki Kitai、Akiyoshi Kanazawa、Akira Yamauchi 和 Yoshio Yamaoka.:“重组白细胞介素 2 治疗乳腺癌血管肉瘤;疗效
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
露木 茂: "肝類洞内リンパ球の肝内腫瘍進展性における関与とそのレドックス制御" 肝類洞壁細胞研究の進歩. 第10巻. 125-128 (1997)
Shigeru Tsuyuki:“肝窦淋巴细胞参与肝内肿瘤进展及其氧化还原调节”肝窦壁细胞研究进展,第 10 卷,125-128 (1997)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMAOKA Yoshio其他文献

YAMAOKA Yoshio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMAOKA Yoshio', 18)}}的其他基金

Biological searches for factors interacted with Helicobacter pylori virulence factor OipA
幽门螺杆菌毒力因子 OipA 相互作用因子的生物学搜索
  • 批准号:
    24659200
  • 财政年份:
    2012
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Clarification of mechanisms how H. pylori virulence factor OipA produces cytokines
阐明幽门螺杆菌毒力因子 OipA 产生细胞因子的机制
  • 批准号:
    22390085
  • 财政年份:
    2010
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular Epidemiological Studies using Helicobacter pylori
使用幽门螺杆菌进行分子流行病学研究
  • 批准号:
    22659087
  • 财政年份:
    2010
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
The research to establish the orader-made therapy system for hepatocellular carcinoma patients by use of genome-wide microarray database
利用全基因组芯片数据库建立肝癌患者定制治疗体系的研究
  • 批准号:
    13357013
  • 财政年份:
    2001
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Activation of regeneration capacity of the cirrhotic livers based on the molecular and genetic biology
基于分子和遗传生物学的肝硬化肝脏再生能力的激活
  • 批准号:
    11307022
  • 财政年份:
    1999
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Moduration of the molecular chaperone activity to increase the safety of extended liver surgery in the damaged liver patients -- challenge by the induction of stress response and heat shock gene transfection --
调节分子伴侣活性以提高肝损伤患者扩大肝脏手术的安全性——诱导应激反应和热休克基因转染的挑战——
  • 批准号:
    09307026
  • 财政年份:
    1997
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Comparative study of immunological tolerance in the liver transplantation from cadaver and living donor
尸体肝移植与活体肝移植免疫耐受的比较研究
  • 批准号:
    08044278
  • 财政年份:
    1996
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
Non-touch isolation hepatectomy and extra-corporeal anticancer therapy for liver tumors-Feedback of surgical technique in living-related partial liver transplantation to liver surgery-
非接触隔离肝切除及肝脏肿瘤体外抗癌治疗-活体部分肝移植手术技术对肝脏手术的反馈-
  • 批准号:
    07407035
  • 财政年份:
    1995
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Comperative study in the viability of the liver graft harvested from cadaver and living donor, evaluated by assessment of tissue oxygenation in sinusoid and oxidation of hepatocyte
通过评估肝窦组织氧合和肝细胞氧化来评估从尸体和活体供体中获取的肝移植物的活力的比较研究
  • 批准号:
    06044127
  • 财政年份:
    1994
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
Perioperative management in clinical liver traus plantation
临床肝外伤种植术的围手术期处理
  • 批准号:
    04044098
  • 财政年份:
    1992
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for international Scientific Research

相似国自然基金

沉默HBX基因表达治疗肝癌的研究
  • 批准号:
    30371402
  • 批准年份:
    2003
  • 资助金额:
    20.0 万元
  • 项目类别:
    面上项目

相似海外基金

Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8731891
  • 财政年份:
    2013
  • 资助金额:
    $ 3.14万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8613538
  • 财政年份:
    2013
  • 资助金额:
    $ 3.14万
  • 项目类别:
Hepatic Non-viral Gene Therapy
肝脏非病毒基因治疗
  • 批准号:
    8882415
  • 财政年份:
    2013
  • 资助金额:
    $ 3.14万
  • 项目类别:
Gene therapy against hepatocellular carcinoma using p48 gene
使用p48基因针对肝细胞癌的基因治疗
  • 批准号:
    13670529
  • 财政年份:
    2001
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic study for. Cancer Gene Therapy by Antitumor Effects Using Fas-Fas Ligand-Mediated Apoptosis
基础学习。
  • 批准号:
    12671144
  • 财政年份:
    2000
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Radio-inducible Dormancy in Hepatoma Gene Therapy
肝癌基因治疗中的放射诱导休眠
  • 批准号:
    11670514
  • 财政年份:
    1999
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene therapy for hepatocellular carcinoma using an endogenous antineoangiogenetic factor, angiostatin
使用内源性抗血管生成因子血管抑制素对肝细胞癌进行基因治疗
  • 批准号:
    11670513
  • 财政年份:
    1999
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene therapy for hepatocellular carcinoma
肝细胞癌的基因治疗
  • 批准号:
    11670516
  • 财政年份:
    1999
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of an ankyrin repeat protein, gankyrin, overexpressed in cancers and its applicating gene therapy
癌症中过度表达的锚蛋白重复蛋白gankyrin的功能分析及其应用基因治疗
  • 批准号:
    10670467
  • 财政年份:
    1998
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A study for cancer gene therapy through Fas-mediated apoptosis
通过 Fas 介导的细胞凋亡进行癌症基因治疗的研究
  • 批准号:
    10671099
  • 财政年份:
    1998
  • 资助金额:
    $ 3.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了